VERAXA Biotech (NASDAQ: VRXA) has announced a collaboration with closely held AI partner Ardigen to support VERAXA’s growing BiTAC pipeline of T-cell engagers and antibody-drug conjugates.
According to VERAXA, the collaboration is another milestone in its mission to integrate AI into its research and development, with the long-term goal to achieve success rates in drug development that exceed industry benchmarks.
In a statement, Christoph Antz, PhD, CEO and co-founder of VERAXA, commented, “We see enormous potential in the application of AI processes to help guide the development strategy of our proprietary BiTAC programs. Because of the nature of BiTACs, smart cancer target selection and thorough validation from the outset can have a transformative impact on future success rates and product profiles. This collaboration represents a strategic step forward in harnessing the power of AI to bring precision oncology therapies to patients faster.”
